Cellia Science, Inc. develops label-free technology for point-of-care hematology, enabling rapid and accurate blood cell assays, including 5-part white blood cell differentials and platelet counts. This technology reduces result turnaround time from hours or days to minutes, facilitating timely clinical decision-making.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional hematology testing requires sending samples to a centralized lab, resulting in turnaround times that can delay diagnosis and treatment decisions. The need for specialized equipment and trained personnel limits access to rapid blood cell analysis in point-of-care settings.
Solution
Cellia Science is developing a label-free hematology analyzer designed for point-of-care use, enabling rapid and accurate blood cell assays directly in the clinic. The device performs 5-part white blood cell differentials and platelet counts, providing results in minutes rather than hours or days. By eliminating the need for sample transport and complex lab procedures, Cellia's technology aims to facilitate timely clinical decision-making and improve patient outcomes. The system is intended to bring high-quality visualization and accurate quantitative measurement of all blood cell types to the point of care.
Target Audience
The primary target audience includes clinicians, hospitals, and point-of-care facilities seeking rapid and accurate hematology results for timely diagnosis and treatment.
Features
- Label-free technology for blood cell analysis
- Rapid 5-part white blood cell differentials
- Accurate platelet counts
- Point-of-care operation for immediate results
- High-quality visualization of blood cell types
- Quantitative measurement of blood cell populations